Development and Characterization of Desmoglein-3 Specific T cells from Japanese Patients with Pemphigus Vulgaris

日本寻常型天疱疮患者 Desmoglein-3 特异性 T 细胞的发育和表征

基本信息

  • 批准号:
    10670804
  • 负责人:
  • 金额:
    $ 2.43万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1998
  • 资助国家:
    日本
  • 起止时间:
    1998 至 1999
  • 项目状态:
    已结题

项目摘要

The purpose of this study is to investigate the response of T lymphocytes from Japanese patients with pemphigus vulgaris (PV) to Desmoglein 3, the autoantigen of PV, and to characterize the properties of Dsg 3-specific T cells.1. We performed high resolution HLA class II typing in 14 Japanese PV patients presented from Dr Amagai using the PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) method. There was a significant association of either DRB 1*14 (14/14:100%), DQB1*0503 (12/14:85%), or DQB1*0301(9/12:64%), when compared with healthy individuals. 2. The 11 recombinant Dsg 3 fusion proteins (Dsg 3. 1-11) with Maltose Binding Protein (MBP) were prepared to encompass each 40 amino acids staggered by 15 residues, starting from the EC 1 of Dsg 33. Autoreactive T cell responses to Dsg 3 were investigated in 14 PV patients and 20 healthy controls by coculture of PBMC with the 11 recombinant Dsg 3 fusion proteins and the incorporation of [ィイD13ィエD1H]-thymidine. Primary in vitro T cell responses (SI=1.9-2.7) to Dsg 3.9 (residues 201-204) or Dsg 3.10 (residues 226-265) were observed in 11/14 PV patients and 7/14 healthy individuals expressing the PV-associated HLA-DRB1*14 and DQB1*05. In contrast, PBMC from 6 normal controls carrying HLA class II alleles other than DRB1*14 and DQB1*05 were not stimulated by recombinant Dsg 3 fusion proteins. These observations demonstrate that T cell response to Dsg 3 can be detected in PV patients and in healthy donors carrying major histocompatibility complex class II alleles identical or similar to those highly prevalent in PV. And that suggests EC2-3 region of the Dsg 3 molecule may contain epitopes that are recognized by Dsg 3-specific T cell. This study will allow us to further develop and characterize the Dsg 3-specific T cell clone in Japanese PV patients.
本研究的目的是调查日本寻常型天疱疮 (PV) 患者的 T 淋巴细胞对 PV 自身抗原 Desmoglein 3 的反应,并表征 Dsg 3 特异性 T 细胞的特性。1.我们使用 PCR-RFLP(聚合酶链反应-限制性片段长度多态性)方法对 Amagai 博士介绍的 14 名日本 PV 患者进行了高分辨率 HLA II 类分型。与健康个体相比,DRB 1*14 (14/14:100%)、DQB1*0503 (12/14:85%) 或 DQB1*0301(9/12:64%) 存在显着相关性。 2. 制备 11 个带有麦芽糖结合蛋白 (MBP) 的重组 Dsg 3 融合蛋白 (Dsg 3. 1-11),以涵盖每 40 个氨基酸,从 Dsg 33 的 EC 1 开始,每 40 个氨基酸错开 15 个残基。通过将 PBMC 与 11 个重组蛋白共培养,在 14 名 PV 患者和 20 名健康对照中研究了对 Dsg 3 的自身反应性 T 细胞反应。 Dsg 3 融合蛋白和[ィイD13ィエD1H]-胸苷的掺入。在表达 PV 相关 HLA-DRB1*14 和 DQB1*05 的 11/14 PV 患者和 7/14 健康个体中观察到对 Dsg 3.9(残基 201-204)或 Dsg 3.10(残基 226-265)的初级体外 T 细胞反应(SI=1.9-2.7)。相比之下,来自携带除DRB1*14和DQB1*05之外的HLA II类等位基因的6个正常对照的PBMC未受到重组Dsg 3融合蛋白的刺激。这些观察结果表明,在携带与PV中高度流行的主要组织相容性复合体II类等位基因相同或相似的PV患者和健康供体中可以检测到对Dsg 3的T细胞反应。这表明 Dsg 3 分子的 EC2-3 区域可能包含被 Dsg 3 特异性 T 细胞识别的表位。这项研究将使我们能够进一步开发和表征日本真性红细胞增多症患者中的 Dsg 3 特异性 T 细胞克隆。

项目成果

期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Amagai Masayuki: "Autoimmunity against desmosomal cadherins in pemphigus"J Dermatol Sci.. 20. 92-102 (1999)
Amagai Masayuki:“天疱疮中针对桥粒钙粘蛋白的自身免疫”J Dermatol Sci.. 20. 92-102 (1999)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Amagai Masayuki: "Usefulness of enzyme-linked immunosorbent assay (ELISA) using reconbinant desmogleins 1 and 3 for serodiagnisis of pemphigus"British Journal of Dermatology. 140. 351-357 (1999)
Amagai Masayuki:“使用重组桥粒芯糖蛋白 1 和 3 进行酶联免疫吸附测定 (ELISA) 对天疱疮血清学诊断的有用性”《英国皮肤病学杂志》。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Amagai Masayuki: "The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile"J Am Acad Dermatol. 40. 167-170 (1999)
Amagai Masayuki:“天疱疮的临床表型是由抗桥粒芯糖蛋白自身抗体谱定义的”J Am Acad Dermatol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Amagai Masayuki: "Autoimmunology against desmosomal cadherins in pemphigus"Journal of Dermatological Science. 20. 92-102 (1999)
Amagai Masayuki:“针对天疱疮桥粒钙粘蛋白的自身免疫学”皮肤病学杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Nishifuji koji: "Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot (ELISPOT) Assay: requirement of T cell collaboration for autoanlibody production."J Invest Dermatol. 114(1). 88-94 (2000)
Nishifuji koji:“通过酶联免疫斑点 (ELISPOT) 检测寻常型天疱疮患者的抗原特异性 B 细胞:自身抗体生产需要 T 细胞协作。”J Invest Dermatol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SAKURAI Toshiharu其他文献

SAKURAI Toshiharu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SAKURAI Toshiharu', 18)}}的其他基金

Molecular link between stress response and cancer and its clinical implication
应激反应与癌症之间的分子联系及其临床意义
  • 批准号:
    17K09396
  • 财政年份:
    2017
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel molecular target in colorectal cancer and inflammatory bowel disease
结直肠癌和炎症性肠病的新分子靶点
  • 批准号:
    26460979
  • 财政年份:
    2014
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translational research focusing on the regulation of proteasome by Gankyrin
Gankyrin对蛋白酶体调控的转化研究
  • 批准号:
    23590998
  • 财政年份:
    2011
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of the resistance mechanisms of immunotherapy by the abnormal signal transduction in melanoma and development of methods to overcome it
阐明黑色素瘤中异常信号转导引起的免疫治疗耐药机制并开发克服该机制的方法
  • 批准号:
    21591445
  • 财政年份:
    2009
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The study of immunosuppressive mechanisms induced by gastrointestinal cancer during epithelial-mesnchymal transition and clinical application of this target therapy
胃肠癌上皮间质转化过程中免疫抑制机制的研究及靶向治疗的临床应用
  • 批准号:
    18591484
  • 财政年份:
    2006
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of novel autoantigens using human IgG in SCID mice implanted with lacrimal and salivary grands from patients with Sjogren's Syndrome
在植入干燥综合征患者泪腺和唾液腺的 SCID 小鼠中使用人 IgG 鉴定新型自身抗原
  • 批准号:
    16590324
  • 财政年份:
    2004
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Using soluble HLA-peptide tetramer, the studies on the cloning and immune-response monitoring of melanoma antigen-specific cytotoxic lymphocyte
利用可溶性HLA肽四聚体进行黑色素瘤抗原特异性细胞毒性淋巴细胞克隆及免疫反应监测的研究
  • 批准号:
    13670901
  • 财政年份:
    2001
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Using solubel peptide-MHC tetramer, the trial of staining and cloning the melanoma antigen-specific cytotoxic lymphocytes
利用可溶性肽-MHC四聚体染色和克隆黑色素瘤抗原特异性细胞毒性淋巴细胞的试验
  • 批准号:
    11670849
  • 财政年份:
    1999
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2022
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10581488
  • 财政年份:
    2022
  • 资助金额:
    $ 2.43万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574979-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 2.43万
  • 项目类别:
    University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10332251
  • 财政年份:
    2022
  • 资助金额:
    $ 2.43万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574984-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 2.43万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574985-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 2.43万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574978-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 2.43万
  • 项目类别:
    University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
  • 批准号:
    444149
  • 财政年份:
    2021
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
  • 批准号:
    RGPIN-2015-05491
  • 财政年份:
    2021
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2021
  • 资助金额:
    $ 2.43万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了